Life Sciences Directory

Planta was founded in 1994 by three dynamic biotechnologists whose aim was to put their ideas and visions into practice. Today Planta is an innovative drug development company. Our staff members’ academic backgrounds lie in the fields of biochemistry, biology, pharmacology and toxicology. Our permanent key personal consists of seven co-workers – a group which allows for a compact and familiar atmosphere. Flexibility is our strength and is a great asset to our customers and cooperation partners.

Based on a highly innovative therapeutic concept ProFem develops new medicines for gynecological diseases which are characterized by a hitherto unmet medical need and high market potential. ProFem’s activities are currently focused on infectious diseases of the female lower genitourinary tract associated with the growth of biofilms.

Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase where it is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete and selective elimi

QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

Revo Foods is a food tech company in Vienna, Austria, that develops new Food Production Systems based on Additive Manufacturing. The goal is to create new food textures for protein-rich products.

RIANA Therapeutics' approach to drug discovery is based on its proprietary platform technology for discovering compounds that target cancer-promoting protein-protein interactions (PPIs). Using this novel approach, RIANA is searching for inhibitors that block the formation of specific oncogenic PPIs. RIANA is currently working to develop new compounds that specifically target acute myeloid leukemia (AML) as well as other blood cancers and certain types of solid tumors.

Ribbon BIolabs is biotechnology company that makes long, highly complex and pristine DNA molecules. We are able to make these molecules through our manufacturing platform that combines our intelligent algorithm with our proprietary enzymes and automated manufacturing line. Our molecules enable breakthroughs to better the health of both people and planet.